ADMA Biologics, Inc.
Case Overview
56 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 08/10/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: ADMA Biologics, Inc. |
| Court: | Court: District of New Jersey |
| Case Number: | Case Number: 2:26cv06918 |
| Class Period: | Class Period: 08/09/2024 - 03/25/2026 |
| Ticker: | Ticker: ADMA |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) securities during the period of August 9, 2024 through March 25, 2026, inclusive (“the Class Period”).
The lawsuit alleges that (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; and (3) ADMA lacked adequate internal controls.
On March 24, 2026, Culper Research published a short seller report on ADMA alleging “Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” Among other things, the report stated that “two high-level employees at one of ADMA's two largest distributors,” had confirmed independently that “starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there.” On this news, the price of ADMA shares declined by $2.26 per share, or approximately 17%, from $13.59 per share on March 23, 2026 to close at $11.33 on March 24, 2026. The price of ADMA shares declined further by $1.70 per share, or approximately 15%, from $11.33 on March 24, 2026 to close at $9.63 on March 25, 2026.
On March 26, 2026, Investing.com published an article that reported “Cantor Fitzgerald downgraded ADMA … following pressure on the shares from a short report alleging the company is boosting ASCENIV revenues through channel stuffing … Cantor Fitzgerald said it expected more specific feedback addressing the direct claims in the short report. Cantor Fitzgerald said the lack of clarity makes it difficult to recommend investors take advantage of stock weakness … The firm said investors are looking for a more thoughtful response from the company and want ADMA Biologics to address cash flow inconsistencies. On this news, the price of ADMA shares declined by $1.34 per share, or approximately 14%, from $9.63 per share on March 25, 2026 to close at $8.29 on March 26, 2026.
The lawsuit alleges that (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; and (3) ADMA lacked adequate internal controls.
On March 24, 2026, Culper Research published a short seller report on ADMA alleging “Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” Among other things, the report stated that “two high-level employees at one of ADMA's two largest distributors,” had confirmed independently that “starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there.” On this news, the price of ADMA shares declined by $2.26 per share, or approximately 17%, from $13.59 per share on March 23, 2026 to close at $11.33 on March 24, 2026. The price of ADMA shares declined further by $1.70 per share, or approximately 15%, from $11.33 on March 24, 2026 to close at $9.63 on March 25, 2026.
On March 26, 2026, Investing.com published an article that reported “Cantor Fitzgerald downgraded ADMA … following pressure on the shares from a short report alleging the company is boosting ASCENIV revenues through channel stuffing … Cantor Fitzgerald said it expected more specific feedback addressing the direct claims in the short report. Cantor Fitzgerald said the lack of clarity makes it difficult to recommend investors take advantage of stock weakness … The firm said investors are looking for a more thoughtful response from the company and want ADMA Biologics to address cash flow inconsistencies. On this news, the price of ADMA shares declined by $1.34 per share, or approximately 14%, from $9.63 per share on March 25, 2026 to close at $8.29 on March 26, 2026.